Evotec AG
EVO Healthcare Drug Manufacturers Specialty & Generic
Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024. In the quarter to June 2026, revenue fell 13.0%, EPS fell 328.9%, free cash flow fell 9,727.2% and total debt rose 5.48%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow EVO
Evotec AG (EVO) P/E ratio
Evotec AG has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,286× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 30.9× | (97.05%) |
| FY2020 | 1,049× | 1,027.72% |
| FY2019 | 93.0× | 205.74% |
| FY2018 | 30.4× | (66.58%) |
| FY2017 | 91.0× | 157.13% |
| FY2016 | 35.4× | 17.45% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| EVO Evotec AG | n/m |
| TLRY Tilray Brands, Inc. compare | n/m |
| EOLS Evolus, Inc. compare | n/m |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 4.4× |
| COLL Collegium Pharmaceutical, Inc. compare | 15.2× |
| KMDA Kamada Ltd. compare | 20.4× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)